Sandoz has fired a defensive shot in a US court against the potential that it may have to fork up higher rebates for two of its drugs via the Centers for Medicare & Medicaid Services’ Medicaid drug rebate program – six years after the suggestion was first made.
Sandoz has filed what it terms a “defensive” lawsuit against the US Centers for Medicare & Medicaid Services, stemming from the potential that two of its drugs could be classified as ‘innovator’ drugs under the Medicaid drug rebate program statute and therefore subject to higher rebates.
Six years ago, the CMS advised Sandoz – but importantly, according to Sandoz, did not render a final a decision...
A ruling from Ireland’s High Court has cleared the way for Endo and Mallinckrodt to consummate their merger in early August.
Trump’s FTC has carried on two legacies – trying to eliminate improper drug patent listings and making minimal impact on such efforts.
As a standalone generics and biosimilars company, Sandoz now feels freer to speak out against originator abuses of intellectual property, the firm’s global IP head Julia Pike tells Generics Bulletin, including challenges to Bayer on rivaroxaban and Amgen on etanercept.
The Federal Circuit has temporarily blocked MSN from launching a generic version of Entresto, granting Novartis short-term relief while it reviews the company’s emergency Rule 8 motion for a longer injunction.
